Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency
Abstract Multiple sulfatase deficiency (MSD, MIM #272200) results from pathogenic variants in the SUMF1 gene that impair proper function of the formylglycine‐generating enzyme (FGE). FGE is essential for the posttranslational activation of cellular sulfatases. MSD patients display reduced or absent...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Springer Nature
2023-02-01
|
| Ráidu: | EMBO Molecular Medicine |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.15252/emmm.202114837 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
